283 related articles for article (PubMed ID: 16912159)
1. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
2. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
5. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
6. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.
Xu W; Bi Y; Kong J; Zhang J; Wang B; Li K; Tian M; Pan X; Shi B; Gu J; Jiang H; Kong X; Li Z
Oncotarget; 2016 Apr; 7(17):24752-65. PubMed ID: 27029073
[TBL] [Abstract][Full Text] [Related]
7. Blockade of glioma proliferation through allosteric inhibition of JAK2.
He K; Qi Q; Chan CB; Xiao G; Liu X; Tucker-Burden C; Wang L; Mao H; Lu X; McDonald FE; Luo H; Fan QW; Weiss WA; Sun SY; Brat DJ; Ye K
Sci Signal; 2013 Jul; 6(283):ra55. PubMed ID: 23838182
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
10. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation.
Xia Q; Zhang H; Zhang P; Li Y; Xu M; Li X; Li X; Dong L
Oncogene; 2020 Sep; 39(36):5902-5915. PubMed ID: 32737433
[TBL] [Abstract][Full Text] [Related]
12. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
[TBL] [Abstract][Full Text] [Related]
13. Will kinase inhibitors make it as glioblastoma drugs?
Mellinghoff IK; Schultz N; Mischel PS; Cloughesy TF
Curr Top Microbiol Immunol; 2012; 355():135-69. PubMed ID: 22015553
[TBL] [Abstract][Full Text] [Related]
14. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Fontana AO; Piffaretti D; Marchi F; Burgio F; Faia-Torres AB; Paganetti P; Pinton S; Pieles U; Reinert M
J Neurooncol; 2017 Jul; 133(3):497-507. PubMed ID: 28500562
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
16. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
[TBL] [Abstract][Full Text] [Related]
17. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Klingler S; Guo B; Yao J; Yan H; Zhang L; Vaseva AV; Chen S; Canoll P; Horner JW; Wang YA; Paik JH; Ying H; Zheng H
Cancer Res; 2015 May; 75(10):2109-19. PubMed ID: 25808866
[TBL] [Abstract][Full Text] [Related]
18. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Filbin MG; Dabral SK; Pazyra-Murphy MF; Ramkissoon S; Kung AL; Pak E; Chung J; Theisen MA; Sun Y; Franchetti Y; Sun Y; Shulman DS; Redjal N; Tabak B; Beroukhim R; Wang Q; Zhao J; Dorsch M; Buonamici S; Ligon KL; Kelleher JF; Segal RA
Nat Med; 2013 Nov; 19(11):1518-23. PubMed ID: 24076665
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.
Li S; Guo W; Gao Y; Liu Y
Tumour Biol; 2015 Apr; 36(4):2607-12. PubMed ID: 25431263
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells.
Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P
Tumour Biol; 2017 Mar; 39(3):1010428317695921. PubMed ID: 28351321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
